Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced a virtual R&D Day scheduled for Oct. 2, 2024, at 10:00 a.m. ET. The event will focus on the company's strategic vision and the development of sabirnetug, their novel treatment for early Alzheimer's disease (AD) that targets toxic soluble amyloid beta oligomers (AβOs).
The webcast will feature Acumen's management and scientific leadership, along with external key opinion leaders including:
- Dr. Stephen Salloway, Director of the Memory and Aging Program at Butler Hospital and Professor at Brown University
- Dr. Paul Solomon, Founder of the Boston Center for Memory and investigator in the ongoing Phase 2 ALTITUDE-AD trial for sabirnetug
Participants can register for the live conference call and access the webcast through links provided. An archived version will be available on Acumen's website for at least one year.
Acumen Pharmaceuticals (NASDAQ: ABOS) ha annunciato una Giornata di Ricerca e Sviluppo virtuale programmata per il 2 ottobre 2024, alle 10:00 a.m. ET. L'evento si concentrerà sulla visione strategica dell'azienda e sullo sviluppo di sabirnetug, il loro nuovo trattamento per l'Alzheimer precoce (AD) che mira a colpire gli oligomeri tossici solubili dell'amiloide beta (AβOs).
Il webcast presenterà la direzione e la leadership scientifica di Acumen, insieme a esperti esterni di rilevanza, tra cui:
- Dr. Stephen Salloway, Direttore del Programma Memoria e Invecchiamento presso il Butler Hospital e Professore presso la Brown University
- Dr. Paul Solomon, Fondatore del Boston Center for Memory e investigatore nello studio in corso di Fase 2 ALTITUDE-AD per sabirnetug
I partecipanti possono registrarsi per la conference call dal vivo e accedere al webcast tramite i link forniti. Una versione archivistica sarà disponibile sul sito web di Acumen per almeno un anno.
Acumen Pharmaceuticals (NASDAQ: ABOS) ha anunciado un Día de I+D virtual programado para el 2 de octubre de 2024 a las 10:00 a.m. ET. El evento se centrará en la visión estratégica de la compañía y el desarrollo de sabirnetug, su nuevo tratamiento para la enfermedad de Alzheimer temprano (AD) que apunta a los oligómeros solubles tóxicos de beta-amiloide (AβOs).
El webcast contará con la participación de la dirección de Acumen y su liderazgo científico, así como líderes de opinión externos, entre ellos:
- Dr. Stephen Salloway, Director del Programa de Memoria y Envejecimiento en el Butler Hospital y Profesor en la Brown University
- Dr. Paul Solomon, Fundador del Boston Center for Memory e investigador en el ensayo de Fase 2 ALTITUDE-AD para sabirnetug
Los participantes pueden registrarse para la conferencia en vivo y acceder al webcast a través de los enlaces proporcionados. Una versión archivada estará disponible en el sitio web de Acumen durante al menos un año.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 2024년 10월 2일 오전 10시(ET)에 예정된 가상 연구 개발의 날을 발표했습니다. 이 행사에서는 회사의 전략적 비전과 조기 알츠하이머병(AD) 치료제인 sabirnetug의 개발에 초점을 맞출 것입니다. 이 치료제는 독성 용해성 아밀로이드 베타 올리고머(AβOs)를 표적으로 합니다.
웹캐스트에는 Acumen의 경영진과 과학적 리더십, 그리고 외부 주요 의견 리더들이 참여할 예정입니다:
- Dr. Stephen Salloway, Butler Hospital의 메모리 및 노화 프로그램 이사 및 Brown University의 교수
- Dr. Paul Solomon, Boston Center for Memory의 창립자이자 sabirnetug의 진행 중인 2상 ALTITUDE-AD 시험 연구원
참가자들은 라이브 컨퍼런스 콜에 등록하고 제공된 링크를 통해 웹캐스트에 액세스할 수 있습니다. 아카이브된 버전은 최소 1년 동안 Acumen의 웹사이트에서 제공될 예정입니다.
Acumen Pharmaceuticals (NASDAQ: ABOS) a annoncé une Journée de Recherche et Développement virtuelle prévue le 2 octobre 2024 à 10h00 ET. L'événement se concentrera sur la vision stratégique de l'entreprise et le développement de sabirnetug, leur nouveau traitement pour la maladie d'Alzheimer précoce (AD) qui cible les oligomères bêta-amyloïdes solubles toxiques (AβOs).
Le webinaire présentera la direction et le leadership scientifique d'Acumen, ainsi que des leaders d'opinion externes, notamment :
- Dr. Stephen Salloway, Directeur du Programme de Mémoire et de Vieillissement à l'Hôpital Butler et Professeur à l'Université Brown
- Dr. Paul Solomon, Fondateur du Boston Center for Memory et enquêteur dans l'étude de Phase 2 ALTITUDE-AD pour sabirnetug
Les participants peuvent s'inscrire pour la conférence téléphonique en direct et accéder au webinaire via les liens fournis. Une version archivée sera disponible sur le site web d'Acumen pendant au moins un an.
Acumen Pharmaceuticals (NASDAQ: ABOS) hat einen virtuellen Forschung und Entwicklungstag angekündigt, der für den 2. Oktober 2024 um 10:00 Uhr ET geplant ist. Die Veranstaltung wird sich auf die strategische Vision des Unternehmens und die Entwicklung von sabirnetug, ihrer neuartigen Behandlung für frühes Alzheimer (AD), die auf toxische lösliche Amyloid-Beta-Oligomere (AβOs) abzielt, konzentrieren.
Der Webcast wird die Geschäftsführung und wissenschaftliche Leitung von Acumen sowie externe wichtige Meinungsführer präsentieren, darunter:
- Dr. Stephen Salloway, Direktor des Gedächtnis- und Alterungsprogramms am Butler Hospital und Professor an der Brown University
- Dr. Paul Solomon, Gründer des Boston Center for Memory und Prüfer in der laufenden Phase 2 ALTITUDE-AD Studie für sabirnetug
Teilnehmer können sich für den Live-Conference-Call registrieren und über die bereitgestellten Links auf den Webcast zugreifen. Eine archivierte Version wird mindestens ein Jahr lang auf der Website von Acumen verfügbar sein.
- None.
- None.
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the Company will host a virtual R&D Day on Wednesday, Oct. 2 at 10:00 a.m. ET. The webcast will highlight Acumen’s strategic vision, and focus on the mechanistic rationale, pre-clinical and clinical data that support further development of sabirnetug as a treatment for early AD.
Featured Speakers
Acumen management and scientific leadership will be joined by external key opinion leaders who will discuss the current treatment paradigm and unmet need in early Alzheimer’s disease, as well as the potential for sabirnetug as an innovative treatment in this indication.
- Dr. Stephen Salloway, MD, MS, the founding Director of the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, Associate Director of the Brown Center for Alzheimer’s Disease Research, and Professor of Neurology and Psychiatry at the Warren Alpert Medical School of Brown University.
- Dr. Paul Solomon, PhD, the Founder and Clinical Director of the Boston Center for Memory, professor in the Department of Neurology at Boston University School of Medicine and an investigator at Boston University's Alzheimer's Disease Center. Dr. Solomon also serves as an investigator in the ongoing Phase 2 ALTITUDE-AD trial investigating sabirnetug.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast will be available via this link.
An archived version of the webcast will be available for at least one year in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) hosting its virtual R&D Day in 2024?
What is the focus of Acumen Pharmaceuticals' (ABOS) R&D Day presentation?
Who are the key speakers at Acumen Pharmaceuticals' (ABOS) R&D Day event?
What is sabirnetug, the drug being developed by Acumen Pharmaceuticals (ABOS)?
How can investors participate in Acumen Pharmaceuticals' (ABOS) R&D Day?
